Fate sees positive B-cell lymphoma data at #ASCO21; ImaginAb secures funding for CD8 imaging trials
Fate Therapeutics revealed some new data at #ASCO21 for their R/R B-cell lymphoma program on Friday.
The San Diego biotech said interim Phase I data for FT516 revealed eight of 11 patients as of the March cutoff date had achieved an objective response, including six who hit levels of complete response. Four of the patients came from the second dose cohort, while the other seven came from the third dose cohort.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.